This series on “Expectant Management in Genitourinary Malignancies (Prostate, Bladder, Kidney)” is edited by
- Mieke Van Hemelrijck, Translational Oncology & Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King’s College London, London, UK; and
- Netty Kinsella, The Royal Marsden Hospital, London, UK; Translational Oncology & Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King’s College London, London, UK.
Better health awareness, access to healthcare and an improvement in diagnostic tests has led to a significant increase in the early detection and diagnosis of localised urological cancers. Expectant management or active surveillance (AS) is used in localised urological cancers and defined as the initial monitoring of tumour size and or grade, with delayed intervention only in tumours demonstrating clinical progression.
Expectant management in genitourinary malignancies (prostate, bladder, kidney)
Using the Movember Foundation’s GAP3 cohort to measure the effect of active surveillance on patient-reported urinary and sexual function—a retrospective study in low-risk prostate cancer patients
Understanding reasons for non-adherence to active surveillance for low-intermediate risk prostate cancer
Quality of life in patients undergoing surveillance for non-muscle invasive bladder cancer—a systematic review
Endoscopic surveillance for bladder cancer: a systematic review of contemporary worldwide practices
Surveillance for low-risk kidney cancer: a narrative review of contemporary worldwide practices
Trends in urine biomarker discovery for urothelial bladder cancer: DNA, RNA, or protein?
Active surveillance for prostate cancer
The need for research methodology to improve acceptability of long-term surveillance for cancer
Factors that influence patients’ views on treatment decision-making in localised kidney cancer
Active surveillance for prostate cancer—will the discoveries of the last 5 years change the future?
The need for core outcome sets in urological cancer research
The series “Expectant Management in Genitourinary Malignancies (Prostate, Bladder, Kidney) ” was commissioned by the editorial office, Translational Andrology and Urology without any sponsorship or funding. Mieke Van Hemelrijck and Netty Kinsella serve as the unpaid guest editors for the special series.